Physician profile
Jason E Bailey
NPI 1760567481
$10,365.53
in general payments reported to CMS, 2019-2025
26 companies · $2,963 in 2025
The $2,963 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $1,888 · 2023: $1,877 · 2024: $3,214 · 2025: $2,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,709 · Education: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,708.73 |
| Education | $345.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,407.16 | 2021-2025 | |
| Janssen Biotech, INC. | $1,055.04 | 2021-2025 | Tremfya |
| Genzyme Corporation | $629.34 | 2021-2025 | |
| Incyte Corporation | $609.42 | 2022-2025 | Opzelura |
| Hill Dermaceuticals, INC. | $580.45 | 2023-2024 | Tolak |
| Pfizer INC. | $579.88 | 2021-2025 | |
| Ucb, INC. | $569.15 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $543.60 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $451.27 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $446.28 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $398.81 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $390.74 | 2021-2024 | Winlevi, Absorica Ld, Ilumya |
| Amgen INC. | $364.43 | 2022-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $307.06 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $254.29 | 2023-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $224.97 | 2022-2024 | |
| Abbott Laboratories | $134.44 | 2025 | Freestyle Libre 3 |
| Galderma Laboratories, L.P. | $113.24 | 2022-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.43 | 2023-2024 | Spevigo |
| Dermavant Sciences, INC. | $69.09 | 2023-2024 | Vtama |
| Ani Pharmaceuticals, INC. | $44.58 | 2025 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $44.37 | 2022-2023 | Nuzyra |
| Kyowa Kirin, INC. | $23.18 | 2022 | |
| Blueprint Medicines Corporation | $14.64 | 2024 | Ayvakit |
| Kerecis Limited | $13.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Musculoskeletal Transplant Foundation INC. | $12.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.